Skip to main content
All lobbying filings

Avenue Solutions

Avenue Solutions filed a Q1 termination report for Omeros Corporation on July 21, 2025, reporting $80,000 in lobbying income.

Lobbying for Omeros Corporation · Biopharmaceutical company

As filed: AVENUE SOLUTIONS for OMEROS CORPORATION.

All filings by Avenue Solutions · Everything Omeros Corporation has reported

 Filing · LD-2 quarterly report Q1 termination
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Jul 21, 2025
Income
$80,000
What the client paid this registrant for the period.
Client based in
Washington
Representation ended
Mar 31, 2025
The registrant reported terminating its work for this client.

Official filing document

 Government bodies contacted 1

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Budget/Appropriations

Issues related to the FDA and treatment for rare disease

Health Issues

Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)

 Bills named in this filing 2
  • S. 891
    Bipartisan Health Care Act
  • H.R. 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem